- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
New Software Combines Pre-Op MRI Guidance with Live Ultrasound for Brachytherapy Treatment of Prostate Cancer
The MIM Software HDR Prostate reportedly enables clinicians to utilize preoperative MRI guidance and live ultrasound imaging to enhance tumor visualization during high dose-rate (HDR) brachytherapy treatments for prostate cancer.
Offering an array of imaging-guided benefits for enhancing the precison of brachytherapy treatments for prostate cancer, GE HealthCare has launched MIM Symphony HDR Prostate software at the World Congress of Brachytherapy (July 10-13) in National Harbor, Md.
While computed tomography (CT) and ultrasound are commonly utilized in planning brachytherapy treatments, GE HealthCare said the combination of live ultrasound with preoperative magnetic resonance imaging (MRI) guidance can elevate the precision of high dose-rate (HDR) brachytherapy.
One of the benefits of the MIM Symphony HDR Prostate software is a ReSlicer feature that addresses differences between supine MRI views and ultrasound lithotomy procedures, according to GE HealthCare, the manufacturer of the software. (Image courtesy of GE HealthCare.)
Emphasizing the capability of MIM Symphony HDR Prostate to facilitate accurate alignment of MRI contours with live ultrasound, the company said key benefits of the software include:
• use of the ReSlicer tool to address differences between supine MRI views and ultrasound lithotomy procedures;
• optimized needle placement that can be utilized even with movement of the prostate during the procedure; and
• automated digitization of needles on planning images.
(Editor’s note: For additional related content on prostate cancer imaging, click here.)
“I often get the question, what is the best imaging modality for planning HDR prostate procedures, ultrasound or CT? My response is always MRI. MRI guidance enables more confident, precise treatments and reduces toxicity to organs at risk. I’ve had the pleasure of providing my patients with precise treatments using MRI guidance in MIM Symphony HDR Prostate, and I look forward to other clinics having the same opportunity,” noted Peter Rossi, M.D., FABS, a radiation oncologist at Valley View Hospital in Glenwood Springs, Colo., and chairman of the board for the American Brachytherapy Society.
What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC
November 13th 2024Researchers found that new prostate lesion detection on SPECT/CT at the beginning of a second cycle of 177 Lu-PSMA-617 for mCRPC was associated with an over sevenfold higher mortality risk.
AI Segmentation, Intraprostatic Tumor Volume and Metastases: What a New mpMRI Study Reveals
October 29th 2024For patients who received radiotherapy for localized prostate cancer, total intraprostatic tumor volume derived from AI segmentation had a 10 percent higher AUC for predicting seven-year metastases in comparison to a risk model from the National Comprehensive Cancer Network (NCCN).
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
